Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model

American Journal of Ophthalmology

Volumn 130, Issue 6, 2000, Pages 717-723

  Netland, Peter A ^a   Leahy, Charles ^b   Krenzer, Kathleen L ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NEW ENGLAND COLLEGE OF OPTOMETRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMEDASTINE; LEVOCABASTINE; PLACEBO;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SOLUTION; EYE IRRITATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SUSPENSION;

ADOLESCENT; ADULT; AGED; ALLERGENS; BENZIMIDAZOLES; CONJUNCTIVA; CONJUNCTIVITIS, ALLERGIC; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PIPERIDINES; PROSPECTIVE STUDIES; SAFETY; SUSPENSIONS; TREATMENT OUTCOME;

EID: 0034531695     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(00)00689-9     Document Type: Article

References (30)

1. Dart JK, Buckley RJ, Monnickendan M, Prasdad J. Perennial allergic conjunctivitis with seasonal allergic conjunctivitis. Trans Ophthalmol Soc UK 1986;105:513-520.
2. Foster CS. In: Albert DM, Jakobiec F, editors. Principles and practice of ophthalmology. Philadelphia: WB Saunders Company, 1994:190-217.
3. Abelson MB. Levocabastine rated superior for ocular allergy. Ophthalmology Times, February 15, 1992:19-20.
4. Allansmith MR, Ross R. Ocular allergy. Clinical Allergy 1988;18:1-13.
5. Schappert SM. National ambulatory Medical Care Survey: 1994 Summary. Advance data from vital and health statistics, No. 273. Hyattsville, MD: National Center for Health Statistics, 1996.
6. Bussche GV. Levocabastine hydrochloride - antihistaminic. Drugs of the Future 1986;11:841-843.
7. Parys W, Blockhuys S, Janssens M. New trends in the treatment of allergic conjunctivitis. Doc Ophthalmol 1992; 82:353-360.
8. Janssens M. Efficacy of levocabastine in conjunctival provocation studies. Doc Ophthalmol 1992;82:341-351.
9. Rimas M, Kjellman NIM, Blychert LO, Bjorksten B. Topical levocabastine protects better than sodium cromoglycate and placebo in conjunctival provocation tests. Allergy 1990;45: 18-21.
10. Nishimura N, Ito K, Tomioka H, Yoshida S. Inhibition of chemical mediator release from human leukocytes and lung in vitro by a novel antiallergic agent, KB-2413. Immunopharmacol Immunotoxicol 1987;9:511-521.
11. Fukuda T, Saito T, Tajima S, Shimorhara K, Ito K. Antiallergic effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole difumarate (KB-2413). Arzneim Forsh 1984;34: 805-810.
12. 1 antagonist for topical ocular use. J Ocul Pharmacol 1994;10: 665-675.
13. Nakajima S, Tsutani Y, Oishimi M, Doi Y, Yamazaki K, Oba Y. Phase I study of emedastine difumarate (KG-2413). I. Single and consecutive administration with KG-2413 tablets. Separate edition of Kenebo Clinical Report 1989;23(14).
14. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge, a clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990;108:84-88.
15. Stegman R, Miller D. A human model of allergic conjunctivitis. Arch Ophthalmol 1975;93:1354-1361.
16. Proud D, Sweet J, Stein P. Inflammatory mediator release on the conjunctival provocation of allergic subjects with allergen. J Allergy Clin Immunol 1990;85:896-905.
17. Moeller C, Bjorksten B, Nisson G. The precision of the conjunctival provocation test. Allergy 1984;39:37-41.
18. Abelson MB, Smith LM. The conjunctival provocation test: a new method for the evaluation of therapeutic agents. Invest Ophthalmol Visual Sci 1988;29(suppl):45.
19. Bisgaard H, Fort-Hutchinson AW, Charleson S. Detection of leukotriene C4-like immunoreactivity in tear fluid from subjects challenged with specific allergen. Prostaglandins 1984;27:369-376.
20. Kari O, Salo OP, Bjorksten F. Allergic conjunctivitis, total and specific IgE in the tear fluid. Acta Ophthalmol 1985;63:97-106.
21. George MA, Smith LM, Abelson MB. Efficacy of 1% prednisolone sodium phosphate in alleviating the signs and symptoms of allergic conjunctivitis induced by allergen challenge. Invest Ophthalmol Visual Sci 1991;32:736.
22. Abelson MB, George M, Drake M. Evaluation of rimexolone ophthalmic suspension in the antigen challenge model of allergic conjunctivitis. Invest Ophthalmol Visual Sci 1992; 33(suppl):1112.
23. Abelson MB, Smith LM, George MA. A double-masked paired comparison of the effects of 0.5% levocabastine and cromolyn sodium on the signs and symptoms of ocular allergy. Ophthalmology 1991;98(suppl):157.
24. Abelson MB, Paradis A, George MA. Effects of Vascon-A in the allergen challenge model of acute allergic conjunctivitis. Arch Ophthalmol 1990;108:520-524.
25. Leonardi A, Secchi A. Local immunotherapy in allergic conjunctivitis. Invest Ophthalmol Vis Sci 1992;33:851-862.
26. Giovanni M, Spada E, Broccoli MP. Conjunctival provocation tests in suspected allergic conjunctivitis. A clinical study. Ophthalmology 1990;201:1-9.
27. Fukuda T, Saito T, Ito K. Antiasthmatic effect of 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl) benzimidazole difumarate 9KB-2413), a new antiallergic. Arzneimittelforschung 1984;34:811-815.
28. 1-selective antagonist, and other ocular employed antihistamines. Drug Dev Res 1994;33:448-453.
29. Berdy GJ, Abelson, MB, George MA, Smith LM, Giovanoni RL. Allergic conjunctivitis: a survey of new antihistamines. J Ocular Pharmacol 1991;7:313-324.
30. Dechant KL, Goa KL. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991;41:202-224.